Evidence map›Paper›PMID 24241579›Full record

ArticleBone marrow transplantation2014

A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality.

M Labopin, N-C Gorin, E Polge, G Socié, G Gurman, E Gluckman, P Jindra, X Poiré, K Schäfer-Eckart, T Ruutu and 5 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2016
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 8 countries.

M Labopin1] Paris EBMT Data Coordination Office, Hospital Saint-Antoine, APHP, Université Pierre et Marie Curie UPMC and INSERM U 938, Paris, France [2] Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Paris, France.
N-C Gorin1] Paris EBMT Data Coordination Office, Hospital Saint-Antoine, APHP, Université Pierre et Marie Curie UPMC and INSERM U 938, Paris, France [2] Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Paris, France.
E PolgeParis EBMT Data Coordination Office, Hospital Saint-Antoine, APHP, Université Pierre et Marie Curie UPMC and INSERM U 938, Paris, France.
G SociéDepartment of Hematology, APHP, Hospital Saint-Louis, University Paris VII, and Inserm U940, Paris, France.
G GurmanDepartment of Hematology, Adult Stem Cell Transplantation Unit, Ankara University School of Medicine, Ankara, Turkey.
E GluckmanEurocord, Hospital Saint-Louis, Paris, France, and Haematology Department, Bone Marrow Transplant Unit, University of Oxford, Oxford, UK.
P JindraDepartment of Hematology/Oncology, Charles University Hospital, Pilsen, Czech Republic.
X PoiréDepartment of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
K Schäfer-EckartMedizinische Klinik, BMT Unit, Nuremberg, Germany.
T RuutuDepartment of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
G MiloneDivisione Clinicizzata di Ematologia, BMT unit, Ospedale Ferrarotto, Catania, Italy.
W ArceseStem Cell Transplant Unit, Rome Transplant Network, Tor Vergata University of Rome, Rome, Italy.
M Mohty1] Paris EBMT Data Coordination Office, Hospital Saint-Antoine, APHP, Université Pierre et Marie Curie UPMC and INSERM U 938, Paris, France [2] Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Paris, France.
V Rocha1] Paris EBMT Data Coordination Office, Hospital Saint-Antoine, APHP, Université Pierre et Marie Curie UPMC and INSERM U 938, Paris, France [2] Eurocord, Hospital Saint-Louis, Paris, France, and Haematology Department, Bone Marrow Transplant Unit, University of Oxford, Oxford, UK.
Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT)
Inserm · FRUniversity of Oxford · GBAnkara University · TRCharles University · CZCliniques Universitaires Saint-Luc · BEFerrarotto Hospital · ITHelsinki University Hospital · FINuremberg Hospital · DESorbonne Université · FRUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For adults with acute leukemia, it is important to know whether the therapeutic schemes initially planned were actually implemented. The European Group for Blood and Marrow transplantation Acute Leukemia Working Party prospectively followed 695 consecutive patients who were registered at the time of HLA typing. Of 304 patients with an available matched sibling donor (MSD), SCT was planned in 264, chemotherapy in 33 and autografting in 7. For the rest, an unrelated donor (UD) search was initiated in 198. Among these, 117 were transplanted, 114 received chemotherapy and 77 underwent autografting. Probabilities of receiving a planned treatment were 60 and 65% at 1 and 2 years, respectively. Patients scheduled to receive MSD SCT had an 82% probability, whereas those scheduled to undergo UD SCT had a 57% probability, of receiving their transplant at 1 year. The only factor associated with a lower probability of MSD SCT in first remission was delayed HLA typing (HR=0.82; P=0.03). One year after enrollment, 40% of patients did not follow their initial treatment plan. Because OS was 50% only at 3 years and only 57% of the patients without a MSD underwent SCT, this suggests room for improvement in outcomes for adults with acute leukemia.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAdultAgedDisease-Free SurvivalDisease ProgressionEuropeFemaleHLA AntigensHumansLeukemia, Myeloid, AcuteMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaProbabilityProspective StudiesHLA Antigens

Identifiers

PMID24241579
OpenAlexW2024739054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.